DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: OCREVUS (ocrelizumab)
       *****************************************************
       #Post#: 2117--------------------------------------------------
       Two new studies of progressive MS announced, as well as new
       Ocrevus data on long-term disability
   DIR By: agate
       Date: June 14, 2018, 3:10 pm
       ---------------------------------------------------------
       From Business Wire, June 14, 2018, an article based on an
       announcement from Genentech, "Genentech Announces New Ocrevus
       Data on Long-Term Disability Benefits in Primary Progressive
       Multiple Sclerosis and Initiation of Two Global Studies in
       Progressive MS":
  HTML https://www.businesswire.com/news/home/20180613006368/en/Genentech-Announces-New-OCREVUS-Ocrelizumab-Data-Long-Term
       The second new study mentioned in the article might be of
       interest for anyone with SPMS:
       --- Quote ---
       >
       > The second study, named CONSONANCE, will evaluate the efficacy
       of OCREVUS in the complete spectrum of progressive MS (PPMS and
       secondary progressive MS (SPMS)). The CONSONANCE study will
       measure the long-term effectiveness of OCREVUS in progressive MS
       with novel composite disability endpoints, including No Evidence
       of Progression (NEP) and No Evidence of Progression or Active
       Disease (NEPAD), in addition to a wide range of patient-relevant
       measures and advanced MRI outcomes. The four-year, Phase IIIb
       study is currently enrolling 600 people with PPMS or SPMS (in a
       1:1 ratio) from across 26 countries. The study will also explore
       whether technology-enabled, continuous sensor-based and
       self-administered measures may detect changes in disability
       progression earlier than conventional clinical measures.
       --- End Quote ---
       *****************************************************
       Page 1 of 1